Jiangsu Run'an Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd., is an important measure taken by Chiatai  Qingjiang to  respond to the international trend , accelerate the adjustment of industrial structure,   extension of industrial chain, promote the optimization and upgrading of industry, ensure the supply security of Chiatai Qingjiang APIs, explore the international market, accelerate the industrialization of new products, and carry out long-term strategic planning. The project started construction in November 2018, covering an area of 59 mu, with a total investment of 160 million yuan and a total building area of about 25000 square meters. 

The first phase mainly includes the construction of general API production workshop, anti-tumor API production workshop, fermentation workshop, research and development center, quality inspection and laboratory in the multifunction- building, storage, water, gas, energy, sewage treatment, roads and other infrastructure projects., The trial production finish production on July of 2020, with a floor area of about 25000 m2. The DCS system is used as a whole to achieve automatic control in the production process and reach the domestic advanced level.

Main products: Gemcitabine hydrochloride, Celecoxib, bromhexine hydrochloride, Iguratimod ,Apremilast, Tofactinib Citrate ,Crisaborole, Urapidil Hydrochloride ,Sugammadex sodium , Garlicin, Dexmedetomidine Hydrochloride, Rocuronium bromide, Finerenone Sodium risedronate, etc.